Shruti Malu

Shruti Malu joined Immunitas in May 2020 as a seasoned immunologist bringing her extensive expertise in identifying and validating targets for cancer immunotherapy and in leading pre-clinical programs for drug discovery. Prior to joining Immunitas, Shruti was a Senior Scientist at Eli Lilly and Company leading both small and large molecule based drug discovery projects for immuno-oncology. Prior to this, Shruti did her post-doctoral work with Dr. Patrick Hwu at MD Anderson Cancer Center discovering tumor mediated resistance mechanisms to immunotherapy followed by spending time in Levi Garraway’s lab at Dana Farber Cancer Institute where she utilized large scale genomic screening to continue her research into tumor resistance mechanisms. Shruti received her Ph.D. in Immunology from Mount Sinai School of Medicine in NY where she discovered novel roles of Artemis protein that belongs to the Non-Homologous End Joining pathway in development of the adaptive immune system. She received her M.S. in Biological Sciences from the Indian Institute of Science and a B.S. in Human Biology from All India Institute of Medical Sciences.